Modern Medicine Cases

5 things physicians should know about Alex Azar
5 things physicians should know about Alex AzarPresident Donald Trump has nominated the former pharma executive to lead the nation’s healthcare agency.
How to treat patients with delusional parasitosis
How to treat patients with delusional parasitosisDelusional parasitosis or Ekbom’s syndrome is a patient’s mistaken belief that he is infested by parasites such as mites, lice, fleas, spiders, worms, bacteria, or other organisms. Scott Schachter, OD, discusses the challenges ODs face when working with these patients.
Clinical findings supported by new OCTA technology
Clinical findings supported by new OCTA technologySince its FDA clearance, the significant potential of OCTA has been emphasized.
This is why we need to accelerate value-based care
This is why we need to accelerate value-based careMuch like the Accountable Care Act (ACA) debate in 2010, the current political debate over repealing and replacing the ACA is focused on coverage and cost.
Study explores ranibizumab as treatment for ROPIntravitreal ranibizumab (Lucentis, Genentech) appears to be effective for treatment of severe retinopathy of prematurity (ROP) and associated with less persistent suppression of systemic VEGF compared with bevacizumab (Avastin, Genentech), according to research reported by Shunji Kusaka, MD.
Complicated cataracts pose almost no limits for adding MIGSComorbidity of glaucoma poses some increased risks for cataract surgery, but even when there are intraoperative complications during the lens removal procedure, it is almost always possible to still add micro-invasive glaucoma surgery (MIGS), said Reay H. Brown, MD.
PRK enhancement after SMILE favorable after short follow-upSurface ablation performed with mitomycin-C (MMC) seems to be a safe and effective technique for treating residual refractive error after myopic SMILE, said Martin Dirisamer, MD.
Ziv-aflibercept for DME provides BCVA gains, lower dosing burdenResults of a 1-year randomized controlled trial investigating treatment for diabetic macular edema (DME) show that intravitreal ziv-aflibercept (Zaltrap, Sanofi Genzyme) 1.25 or 2.5 mg is safe, according to Masoud Soheilian, MD.
Intranasal neurostimulator shows benefit for increasing tear productionResults from two pivotal multicenter trials demonstrate that an intranasal tear neurostimulator (TrueTear, Allergan) safely and effectively increases endogenous tear production in patients with dry eye disease (DED), said Edward Holland, MD.
IRIS Registry gives glimpse into DME in real worldAn analysis of data collected in the Intelligent Research in Sight (IRIS) Registry suggests that in the real-world setting, newly diagnosed diabetic macular edema (DME) is being vastly undertreated. Not only are the majority of these patients not receiving active intervention, but those who are started on anti-vascular endothelial growth factor (VEGF) therapy seem to be getting a suboptimal number of injections, said Jeffrey R. Willis, MD, PhD.